Trial ID or NCT#



not recruiting iconNOT RECRUITING


The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).

Official Title

A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Yuen So, MD, PhD
Yuen So, MD, PhD
Neuromuscular neurologist, Neurophysiologist
Professor of Neurology

Contact us to find out if this trial is right for you.


Shirely Paulose
(650) 724-3792